Oriol Caritg1, Alfons Navarro2, Isabel Moreno3, Francisco Martínez-Rodenas3, Anna Cordeiro1, Carmen Muñoz1, Marc Ruiz-Martinez1, Sandra Santasusagna1, Joan Josep Castellano1, Mariano Monzó1. 1. Molecular Oncology and Embryology Laboratory, Human Anatomy Unit, School of Medicine, University of Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain. 2. Molecular Oncology and Embryology Laboratory, Human Anatomy Unit, School of Medicine, University of Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain. Electronic address: anavarroponz@ub.edu. 3. Department of Medical Oncology and Surgery, Hospital Municipal de Badalona, Badalona, Spain.
Abstract
BACKGROUND: The potential benefit of adjuvant chemotherapy in surgically resected patients with stage II colorectal cancer is controversial. The current guidelines, which are based solely on clinical factors, have limited usefulness, and a clear need exists for biomarkers to supplement the clinical information. MicroRNAs (miRNAs) have previously been shown to be useful cancer biomarkers. In the present study, we assessed the usefulness of a miRNA score to help identify the subset of high-risk patients likely to benefit from adjuvant chemotherapy. PATIENTS AND METHODS: Six miRNAs previously identified as prognostic markers in Asian patients (miR-21-5p, miR-20a-5p, miR-103a-3p, miR-106b-5p, miR-143-5p, and miR-215) were studied in tumor samples from 71 white patients with stage II colon cancer. RESULTS: Three miRNAs (miR-103a-3p, miR-143-5p, and miR-215) emerged as independent prognostic markers on multivariate analysis and were used to construct a miRNA-based score that classified patients into high- and low-risk groups. The patients in the high-risk group had significantly shorter disease-free survival compared with their low-risk counterparts (P = .003). The time-dependent receiver operating characteristic curve analysis showed that our 3-miRNA score improved the prediction of outcome when added to the clinical features (P = .023). CONCLUSION: Our 3-miRNA score added valuable prognostic information to the clinical features in stage II colon cancer. Further research in this field could provide useful tools to determine whether adjuvant chemotherapy would benefit patients with stage II colon cancer after surgery. Copyright Â
BACKGROUND: The potential benefit of adjuvant chemotherapy in surgically resected patients with stage II colorectal cancer is controversial. The current guidelines, which are based solely on clinical factors, have limited usefulness, and a clear need exists for biomarkers to supplement the clinical information. MicroRNAs (miRNAs) have previously been shown to be useful cancer biomarkers. In the present study, we assessed the usefulness of a miRNA score to help identify the subset of high-risk patients likely to benefit from adjuvant chemotherapy. PATIENTS AND METHODS: Six miRNAs previously identified as prognostic markers in Asian patients (miR-21-5p, miR-20a-5p, miR-103a-3p, miR-106b-5p, miR-143-5p, and miR-215) were studied in tumor samples from 71 white patients with stage II colon cancer. RESULTS: Three miRNAs (miR-103a-3p, miR-143-5p, and miR-215) emerged as independent prognostic markers on multivariate analysis and were used to construct a miRNA-based score that classified patients into high- and low-risk groups. The patients in the high-risk group had significantly shorter disease-free survival compared with their low-risk counterparts (P = .003). The time-dependent receiver operating characteristic curve analysis showed that our 3-miRNA score improved the prediction of outcome when added to the clinical features (P = .023). CONCLUSION: Our 3-miRNA score added valuable prognostic information to the clinical features in stage II colon cancer. Further research in this field could provide useful tools to determine whether adjuvant chemotherapy would benefit patients with stage II colon cancer after surgery. Copyright Â
Authors: Benjamin G Allar; Evangelos Messaris; Vitaliy Y Poylin; Benjamin L Schlechter; Thomas E Cataldo Journal: Med Oncol Date: 2022-02-12 Impact factor: 3.064
Authors: Havjin Jacob; Luka Stanisavljevic; Kristian Eeg Storli; Kjersti E Hestetun; Olav Dahl; Mette P Myklebust Journal: Sci Rep Date: 2018-04-18 Impact factor: 4.379
Authors: Maarten Neerincx; Dennis Poel; Daoud L S Sie; Nicole C T van Grieken; Ram C Shankaraiah; Floor S W van der Wolf-de Lijster; Jan-Hein T M van Waesberghe; Jan-Dirk Burggraaf; Paul P Eijk; Cornelis Verhoef; Bauke Ylstra; Gerrit A Meijer; Mark A van de Wiel; Tineke E Buffart; Henk M W Verheul Journal: PLoS One Date: 2018-08-03 Impact factor: 3.240